Monteleukast

Phase 3Small molecule

HHormozgan University of Medical Sciences

Monteleukast is one of 8 small molecule programs targeting Otitis Media With Effusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Otitis Media With EffusionActive, not recruiting

Otitis Media With EffusionPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Otitis Media With Effusion

#DrugCompanyPhaseTrials

Steroid Drug

PPeking Union Medical College Hospital

Approved

1 2

Kenalog

BBausch Health Americas, Inc.

Phase 3

1 3

Asmanex Hfa

PPerrigo Company

Phase 3

1 4

Asmanex

Novartis

Phase 1

1 5

Monteleukast

HHormozgan University of Medical Sciences

Phase 3

1 6

Prevacid

Takeda

Preclinical

1 7

Singulair

OOrganon and Co

Preclinical

1 8

Prednisolone Sodium Phosphate

UUniversity of Oulu

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Otitis Media With Effusion1 trial

Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children

Completed·HHormozgan University of Medical Sciences·Phase 3·NCT02541760·143 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Monteleukast. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Monteleukast compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Monteleukast. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hormozgan University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHormozgan University of Medical Sciences

Monteleukast

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Otitis Media With Effusion1 trial

References

Drug Info

Quick Facts

Related News